VYNE Therapeutics Inc.

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-04-17 pm EDT			5-day change	1st Jan Change
1.850 ^USD	+2.49%		+25.00%	-44.78%

Apr. 08	Artiva Biotherapeutics Names New Chief Medical Officer	MT
Mar. 17	Mindmed Appoints Matt Wiley as Chief Commercial Officer	CI

Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating

May 12, 2023 at 10:09 am EDT

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about VYNE Therapeutics Inc.

Artiva Biotherapeutics Names New Chief Medical Officer	Apr. 08	MT
Mindmed Appoints Matt Wiley as Chief Commercial Officer	Mar. 17	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Mar. 06	CI
Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis	Feb. 19	RE
VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis	Feb. 19	CI
VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	Jan. 06	CI
VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	Dec. 23	MT
VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor	Dec. 23	CI
BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	Nov. 18	MT
Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	Nov. 07	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor	24-09-12	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $198,000	24-08-14	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	24-07-09	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index	24-06-30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index	24-06-30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Value Index	24-06-30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index	24-06-30	CI
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer	24-06-24	CI
Arvinas, Inc. Appoints Andrew Saik as Treasurer	24-06-24	CI
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	24-06-13	CI
Top Premarket Gainers	24-06-07	MT
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	24-06-05	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	24-05-09	MT

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Employees

Sector

Biotechnology & Medical Research

Calendar

May. 07 - Q1 2025 Earnings Release (Projected)

More about the company